Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435790 | 1.00 | KYNU (0.57) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL1110994 | 0.99 | KYNU (0.56) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL269404 | 0.93 | KYNU (0.62) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL187849 | 0.93 | KYNU (0.62) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL29678939 | 0.93 | KYNU (0.62) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL19410220 | 0.92 | KYNU (0.57) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL13798138 | 0.90 | KYNU (0.56) | KYNUELANEATMKLK1CTRB1 | |
| Lithium Ion SCHEMBL1110992 | 0.89 | KYNU (0.55) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL15549899 | 0.86 | ELANE (0.54) | KYNUELANEATMKLK1CTRB1 | |
| SCHEMBL13798136 | 0.86 | KYNU (0.52) | KYNUELANEATMKLK1CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| EP-3908585-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021013978-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2021-01-28 | — | — | WO | disclosed |
| EP-3681875-A1 | CYCLIC PEPTIDE ANTIBIOTICS | H. Hoffnabb-La Roche Ag (CH) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | US | disclosed |
| US-20060264358-A1 | Acylated nonadepsipeptides II | BAYER HEALTHCARE AG (DE) | 2006-11-23 | — | — | US | disclosed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1625153-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | Bayer HealthCare AG (DE) | 2006-02-15 | — | — | EP | disclosed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| WO-2004099239-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1425286-A1 | SUBSTITUTED 7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003022856-A1 | SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CHRNA7, CHRNA1, CHRNA6 | KYNU 1058/4885ELANE 3219/4885ATM 4066/4885 |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | KYNU 1318/4885ELANE 770/4885ATM 4030/4885 |
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | KYNU 1333/4885ELANE 1675/4885ATM 2227/4885 |
| US-20060264358-A1 | Acylated nonadepsipeptides II | VIP, LYPLA2, ENPP2 | KYNU 3190/4885ELANE 837/4885ATM 4588/4885 |
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | TEK, CD2BP2, SDCBP | KYNU 3591/4885ELANE 1264/4885ATM 3665/4885 |
| US-20200172578-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | CD274, PDCD1, PDCD1LG2 | KYNU 965/4885ELANE 1968/4885ATM 1075/4885 |
| US-11066445-B2 | Immunomodulators acting as antagonists of PD-1 | CD274, PDCD1, PDCD1LG2 | KYNU 1166/4885ELANE 2662/4885ATM 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.